In Part 7 of Elizabeth Holmes’ video deposition, SEC investigators question the former Theranos CEO about the company's tumultuous regulatory interactions, internal communications, and major business relationships. Holmes is questioned regarding: Interactions with the FDA, including 510(k) filings, meeting minutes, and the decision to halt the use of the proprietary Nanotainer blood-collection tube. Text message exchanges between Holmes and former Theranos President Ramesh "Sunny" Balwani during the 2015 FDA inspection, discussing lab marketing strategies and dealing with regulatory scrutiny. The structure, renegotiation, and disputed earn-out terms of the $100M "innovation fee" paid by Walgreens. Claims regarding Theranos technology deployed with the U.S. military and Department of Defense (DoD), including SOCOM, AFRICOM, and CENTCOM. The origin and drafting of pharmaceutical validation reports (Pfizer, GSK, Schering-Plough) distributed in investor binders. Listen To Hidden Killers Podcast ANYWHERE! Listen Here: https://linktr.ee/hiddenkillers Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.